Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Endovascular Treatment of Visceral Artery Pseudoaneurysms with Ethylene-Vinyl Alcohol (EVOH) Copolymer-Based Non-adhesive Liquid Embolic Agents (NALEAs)

Version 1 : Received: 1 August 2023 / Approved: 1 August 2023 / Online: 2 August 2023 (02:33:23 CEST)

A peer-reviewed article of this Preprint also exists.

Minici, R.; Guerriero, P.; Fontana, F.; Venturini, M.; Guzzardi, G.; Piacentino, F.; Coppola, A.; Spinetta, M.; Siciliano, A.; Serra, R.; Costa, D.; Ielapi, N.; Santoro, R.; on behalf of the MGJR Research Team; Brunese, L.; Laganà, D. Endovascular Treatment of Visceral Artery Pseudoaneurysms with Ethylene-Vinyl Alcohol (EVOH) Copolymer-Based Non-Adhesive Liquid Embolic Agents (NALEAs). Medicina 2023, 59, 1606. Minici, R.; Guerriero, P.; Fontana, F.; Venturini, M.; Guzzardi, G.; Piacentino, F.; Coppola, A.; Spinetta, M.; Siciliano, A.; Serra, R.; Costa, D.; Ielapi, N.; Santoro, R.; on behalf of the MGJR Research Team; Brunese, L.; Laganà, D. Endovascular Treatment of Visceral Artery Pseudoaneurysms with Ethylene-Vinyl Alcohol (EVOH) Copolymer-Based Non-Adhesive Liquid Embolic Agents (NALEAs). Medicina 2023, 59, 1606.

Abstract

Background and Objectives: Treatment of visceral artery pseudoaneurysms (VAP) is always indicated regardless of their diameters, as their risk of rupture is significantly higher than that of visceral artery aneurysms. The invasiveness of surgery and its associated complications have led to a shift in favour of radiological interventions as the initial treatment of choice. However, there are still some unanswered questions on endovascular treatment of VAP regarding the optimal endovascular technique and the efficacy and safety outcomes. The purpose of this multicenter study was to retrospectively evaluate the effectiveness and safety of endovascular treatment of visceral pseudoaneurysms using Ethylene-Vinyl Alcohol (EVOH) Copolymer-Based Non-Adhesive Liquid Embolic Agents (NALEAs). Materials and Methods: Consecutive patients who underwent endovascular embolization with EVOH-based NALEAs for visceral artery pseudoaneurysms between January 2018 and June 2023 were retrospectively evaluated. Results: 38 embolizations were performed. Technical success was achieved in all patients. The clinical success rate was high (92.1% overall), with no significant differences between ruptured and unruptured VAPs (p=0.679). 7 patients (18.4%) experienced procedure-related complications, related to a case of non-target embolization, four splenic abscesses due to end-organ infarction and two femoral pseudoaneurysms. The rates of procedure-related complications, end-organ infarction, and vascular access-site complications did not significantly differ between ruptured and unruptured VAPs (p>0.05). Conclusions: Both ruptured and unruptured visceral pseudoaneurysms can be effectively and safely treated with NALEA-based endovascular embolization. We suggest considering the use of NALEAs, particularly in specific clinical cases that highlight their advantages, including patients with coagulopathy, fragile vessels, and embolization targets that are located at a considerable distance from the microcatheter tip and are otherwise difficult to reach.

Keywords

pseudoaneurysm; visceral pseudoaneurysms; TAE; embolization; endovascular treatment; percutaneous; embolic agents; EVOH; NALEA; Onyx

Subject

Medicine and Pharmacology, Emergency Medicine

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.